{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:17:19Z","timestamp":1783707439378,"version":"3.55.0"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":1375,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:p>Selective serotonin reuptake inhibitors (SSRIs) may be associated with electrocardiographic effects. The electrocardiographic pharmacodynamics of dapoxetine, a short\u2010acting SSRI being developed for the treatment of premature ejaculation, are compared with those of placebo and moxifloxacin (positive control) in 2 single\u2010center, randomized, crossover studies in healthy men. In study 1, subjects receive 2 doses of dapoxetine 120 mg, given 3 hours apart; a single dose of moxifloxacin 400 mg; and 2 doses of placebo, given 3 hours apart. In study 2, subjects receive single doses of dapoxetine 60 mg, dapoxetine 120 mg, moxifloxacin 400 mg, and placebo. Moxifloxacin significantly increases QT and corrects QT intervals (QTc) compared with placebo in both studies (eg, Bazett\u2010corrected QTc of 11.90 milliseconds [95% confidence interval, 2.68 to 21.11] and 5.06 [95% confidence interval, \u22122.26 to 12.38]). Dapoxetine 60, 120, and 240 mg do not prolong the QT\/QTc interval and have no clinically significant electrocardiographic effects. Dapoxetine and moxifloxacin pharmacokinetics are similar to previous reports. Adverse events are generally mild in severity; nausea is the most common. The results demonstrate that dapoxetine does not have electrocardiographic effects at doses of 60, 120, and 240 mg.<\/jats:p>","DOI":"10.1177\/0091270009333486","type":"journal-article","created":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T01:21:16Z","timestamp":1240536076000},"page":"634-642","source":"Crossref","is-referenced-by-count":19,"title":["Pharmacokinetics and Pharmacodynamic, Pharmacokinetic, Pharmacodynamic, and Electrocardiographic Effects of Dapoxetine and Moxifloxacin Compared With Placebo in Healthy Adult Male Subjects"],"prefix":"10.1002","volume":"49","author":[{"given":"Nishit B.","family":"Modi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajneesh","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Staehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneel K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Aquilina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2005.20353.x"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/00926230390224738"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.6.537"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2004.04033.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.07.004"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005284850"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69373-2"},{"key":"e_1_2_7_9_2","article-title":"Treatment benefit of dapoxetine for premature ejaculation: results from a placebo\u2010controlled phase III trial [published online ahead of print November 18, 2008]","author":"Kaufman JM","year":"2008","journal-title":"BJU Int"},{"issue":"4","key":"e_1_2_7_10_2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-5347(18)35046-8","article-title":"Dapoxetine for the treatment of men with premature ejaculation (PE): dose\u2010finding analysis","volume":"173","author":"Hellstrom W","year":"2005","journal-title":"J Urol"},{"key":"e_1_2_7_11_2","article-title":"Dapoxetine for the treatment of premature ejaculation: results from a randomized, double\u2010blind, placebo\u2010controlled trial in 22 countries","author":"Buvat J","journal-title":"Eur Urol"},{"key":"e_1_2_7_12_2","unstructured":"McMahonC ParkNC ZhaoY RothmanM RivasD.Treatment of premature ejaculation (PE) in the Asia\u2010Pacific region: results from a phase III double\u2010blind parallel\u2010group study of dapoxetine. Oral presentation at: the 11th Biennial Meeting of the Asia Pacific Society for Sexual Medicine;October 610 2007; Jeju Korea. Abstract OS05_06."},{"key":"e_1_2_7_13_2","first-page":"353","article-title":"An analysis of time relations of electrocardiograms","volume":"7","author":"Bazett HC.","year":"1920","journal-title":"Heart"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1920.tb18266.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00009-2"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979612"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199811000-00004"},{"key":"e_1_2_7_18_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2174\/0929867305666220319103330","article-title":"Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants","volume":"5","author":"Pacher P","year":"1998","journal-title":"Curr Med Chem"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-2-200101160-00022"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200108000-00019"},{"key":"e_1_2_7_21_2","unstructured":"United States Food and Drug Administration.Guidance for Industry. E14. Clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs.http:www.fda.govcbergdlnsiche14qtc.htmii. Accessed January 5 2009."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270009333486","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270009333486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T09:49:15Z","timestamp":1697449755000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270009333486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1177\/0091270009333486"],"URL":"https:\/\/doi.org\/10.1177\/0091270009333486","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}